Munc13-4 inhibitors belong to a specific chemical class designed to target and modulate the activity of the Munc13-4 protein. Munc13-4 is a member of the Munc13 protein family, which plays a crucial role in intracellular membrane trafficking and neurotransmitter release. Located primarily in secretory cells, Munc13-4 is implicated in the regulation of granule exocytosis, particularly in immune cells such as mast cells and cytotoxic T lymphocytes. The protein is known for its involvement in the fusion of secretory vesicles with the cell membrane, a process essential for the release of various signaling molecules.
Chemically, Munc13-4 inhibitors are carefully designed compounds that interact with the Munc13-4 protein, modulating its function and impeding the normal progression of vesicle fusion. These inhibitors are meticulously crafted to interfere with the molecular interactions and signaling cascades involved in the precise orchestration of vesicle release. By targeting Munc13-4, these compounds aim to exert control over the intricate machinery governing exocytosis, potentially influencing various cellular processes. The development of Munc13-4 inhibitors represents a promising avenue for scientific research and has the potential to enhance our understanding of fundamental cellular mechanisms, shedding light on the intricate processes governing vesicle trafficking and exocytosis in diverse cell types.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor that can disrupt vesicle trafficking and autophagy, indirectly affecting UNC13D. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A broad PI3K inhibitor, which can interfere with signaling pathways relevant to vesicle priming. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Inhibits V-ATPase and could disrupt vesicle acidification, impacting vesicle priming. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
V-ATPase inhibitor, similar to Bafilomycin A1, could also disrupt vesicle priming. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
GTPase inhibitor that can prevent vesicle scission, indirectly affecting UNC13D function. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $184.00 $305.00 | 59 | |
Stabilizes actin filaments and can potentially disrupt vesicle transport. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Actin polymerization inhibitor, could impede vesicle movement, impacting UNC13D function. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
CDC42 inhibitor, which can affect actin polymerization and vesicle movement. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
Selective Rac1 inhibitor, potentially disrupting actin dynamics and vesicle trafficking. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Disrupts actin microfilaments and could indirectly affect vesicle priming and trafficking. | ||||||